source
- Medicare uptake of newly approved Alzheimer’s drugs Leqembi and Kisunla falls short of expectationsMedicare is seeing much lower use of the two Alzheimer’s treatments that received FDA approval earlier this year. The drugs, Leqembi and Kisunla, were expected to generate notable spending for Med…
- ctDNA testing shows promise for renal cell carcinoma and germ cell tumors despite current limitationsExperts discussed how circulating tumor DNA (ctDNA) monitoring, long used in bladder cancer, is being explored for renal cell carcinoma (RCC) and germ cell tumors. In RCC, low tumor shedding has l…